



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Richard J. Budhu, et al.

Group No.: 1626

U.S. Serial No.: 10/505,257

Filed: August 20, 2004

Examiner: Chu, Yong Liang

For: AMINOALKYLPHOSPHONATES AND RELATED
COMPOUNDS AS EDG RECEPTOR AGONISTSCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**TERMINAL DISCLAIMER TO OBVIATE
A DOUBLE PATENTING REJECTION**
[37 CFR 1.321]

I, Valerie J. Camara, residing at
980 Glenwood Avenue, Plainfield, NJ 07060, am a representative
of the assignee identified below, empowered to act on its behalf, pursuant to attached
Corporate Resolution No. 5, dated 10/24/2006.

The assignee, Merck & Co., Inc., certifies
that it is the assignee of the entire right, title and interest in the above-identified
patent application by virtue of an Assignment from the inventor(s) in the aforesaid
patent application, which was

- ☒ recorded in the United States Patent & Trademark Office on Reel(s) 019196
Frame(s) 0201 on 04/19/2007,
- ☐ was forwarded for recording on _____, with a copy of the recordation form
and assignment attached hereto, or
- ☐ is being concurrently forwarded for recording under separate cover, with a copy of the
recordation form and assignment attached hereto.

The aforesaid assignment establishes the ownership in the assignee of the above-identified
application pursuant to 37 CFR 3.73(b).

The undersigned has reviewed all of the evidentiary documents in the chain of title of the
above-identified patent application, and the undersigned certifies that, to the best of the
undersigned's knowledge and belief, title is in the assignee named above.

I hereby disclaim the terminal part of the statutory term of any patent granted on the
above-identified application, which would extend beyond the expiration date of the full
statutory term of:

- ☒ United States Patent No. 6,437,165, or as presently shortened by any terminal
disclaimer,
- ☐ Any patent granted on application serial number _____,

05/03/2007 SFELEKE1 00000039 132755 10505257

01 FC:1814 130.00 DA

and hereby agree that any patent so granted on the above-identified application shall be enforceable on, for and during such periods that the legal title to said patent shall be the same as the legal title to:

☒ United States Patent No. 6,437,165 ,

☐ Any patent granted on application serial number _____ ,

this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of:


☒ United States Patent No. 6,437,165 , or as presently shortened by any terminal disclaimer,

☐ Any patent granted on application serial number _____ ,

in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The Commissioner is requested to charge Account No. 13-2755 the sum of \$130.00 and any fee deficiency required by this paper. A duplicate of this disclaimer is attached.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.



Disclaimant Valerie J. Camara

Patent Counsel

Title

Merck & Co., Inc.
Patent Dept., RY60-30
P.O. Box 2000
Rahway, New Jersey 07065-0907
Telephone No. (732) 594-3902

In Duplicate
Attachs.

Date: 04/27/2007

General Corporate Resolution #5

PATENT MATTERS

RESOLVED, that any of the following:

Richard T. Clark—Chief Executive Officer and President
Kenneth C. Frazier-Senior Vice President and General Counsel
Joseph F. DiPrima-Vice President and Assistant General Counsel
Paul D. Matukaitis-Vice President and Assistant General Counsel
William Krovatin-Counsel, IP Litigation
Edward W. Murray-Counsel, IP Litigation
Charles M. Caruso-Counsel, International
Valerie J. Camara-Counsel, Patents
Mark R. Daniel-Counsel, Patents
Joanne M. Giesser-Counsel, Patents
Anthony Rollins-Counsel, European Patents
David L. Rose-Counsel, Patents
Jack L. Tribble-Counsel, Patents
Melvin Winokur-Counsel, Patents
Edward M. Yoshida-Counsel, Rosetta Inpharmatics
John Oksinski-Executive Director, Banyu
Kenichi Osawa-Director, Banyu Patent and Trademark Group
Donna L. Margiotto-Senior Manager, Patent Administration

are authorized to execute and to revoke on behalf of Merck & Co., Inc. and its affiliates (including subsidiaries) the following documents relating to patent matters:


Powers of attorney as fully in law as may be necessary and proper in connection with the acquisition, registration, maintenance and enforcement of patents and applications for patents, including powers of attorney relating to the prosecution or defense of patent rights before courts of law or other governmental tribunals, agencies or departments; affidavits and declarations; and any other documents which are necessary and proper for the acquisition, registration, maintenance, litigation and protection of patents.

MERCK & CO., INC.

CERTIFICATION

I, Debra A. Bollwage, Senior Assistant Secretary of Merck & Co., Inc. (the "Company"), a corporation duly organized and existing under the laws of the State of New Jersey, United States of America, do hereby certify that the attached, presently in full force and effect, is a true and correct copy of General Corporate Resolution #5, Patent Matters, as amended on October 24, 2006 by the Board of Directors of said Company at a meeting thereof duly called and held on October 24, 2006 at which a quorum of Directors was present.

IN WITNESS WHEREOF, I have hereunto subscribed my signature and affixed the seal of the Company this 23rd day of January 2007.



Senior Assistant Secretary

(SEAL)